SynthesisBrain and behavior2026
Comparing Efficacy and Safety of Various Monoclonal Antibodies in Myasthenia Gravis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Synthesis in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyasthenia gravis (MG) is an autoimmune disorder that causes muscle weakness due to disrupted neuromuscular transmission. This network meta-analysis compared the safety and effectiveness of monoclonal antibodies used to treat MG.
methodsPubMed, Cochrane Central, and ScienceDirect were searched through June 2025. A frequentist network meta-analysis was conducted using the "meta" and "netmeta" packages in RStudio version 4.3.3. Treatment rankings were determined by p-scores.
resultsEighteen randomized controlled trials (RCTs) were included in this network meta-analysis. Rozanolixzumab (ROZ) 10 mg/kg significantly decreased the MG Activities of Daily Living (MG-ADL) score compared to placebo (MD = -2.33; 95%CI:[-3.60, -1.06]; p = 0.0003) and was ranked best (p-score = 0.77) regarding this outcome. Batoclimab (BAT) 680 mg significantly reduced the Quantitative MG (QMG) score compared to placebo (MD = -5.17; 95%CI:[-6.44, -3.89]; p <0.0001) and was rated the top performer (p-score = 0.96) for this endpoint. Regarding the MG Composite (MGC) score, BAT 340 mg was ranked best (p-score = 0.82), although the decrease in MGC score was insignificant (MD -5.30; 95%CI:[-11.01, 0.41]; p = 0.07). Eculizumab (ECU) was ranked best (p-score = 0.93) regarding the 15-item revised MG Quality of Life (MG-QoL 15r) score. Belimumab (BEL) 10 mg/kg was ranked best regarding the adverse events (p-score = 0.87).
conclusionROZ 10 mg/kg ranked best for MG-ADL. BAT 680 mg significantly reduced QMG and ranked best. BAT 340 mg had the highest probability of reducing the MGC score. ECU significantly decreased MG-QoL 15r and ranked best. BEL 10 mg/kg had the highest likelihood of reducing adverse events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.